Damkier Per, Gram Erika B, Ceulemans Michael, Panchaud Alice, Cleary Brian, Chambers Christina, Weber-Schoendorfer Corinna, Kennedy Debra, Hodson Ken, Grant Kimberly S, Diav-Citrin Orna, Običan Sarah G, Shechtman Svetlana, Alwan Sura
Department of Clinical Pharmacology, Odense University Hospital, and the Department of Clinical Research, University of Southern Denmark, Odense, Denmark; Clinical Pharmacology & Pharmacotherapy, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium; Radboud University Medical Center, Nijmegen, the Netherlands; Service of Pharmacy, Lausanne University Hospital and University of Lausanne, Lausanne, and the Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland; the Pharmacy Department, Rotunda Hospital and School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland; the Department of Pediatrics, University of California San Diego, La Jolla, California; Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Pharmakovigilanzzentrum, Embryonaltoxikologie, Institut für Klinische Pharmakologie und Toxikologie, Berlin, Germany; Mothersafe, University of New South Wales, Australia; UK Teratology Information Service and the Directorate of Women's Services, Royal Victoria Infirmary, Newcastle Upon Tyne, United Kingdom; the Department of Environmental and Occupational Health Sciences, School of Public Health, University of Washington, Seattle, Washington; the Israeli Teratology Information Service, Ministry of Health, and the Hebrew University Hadassah Medical School, Jerusalem, Israel; the Department of Obstetrics and Gynecology, Morsani College of Medicine, University of South Florida, Tampa, Florida; and the Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
Obstet Gynecol. 2025 Feb 1;145(2):168-176. doi: 10.1097/AOG.0000000000005802. Epub 2024 Dec 5.
Acetaminophen is a common over-the-counter medication that recently gained substantial media attention regarding its use by pregnant individuals. In this clinical perspective, we discuss the strengths and limitations of the published literature on the effect of maternal acetaminophen use in pregnancy on the child's risk of developing attention-deficit and hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). Studies included were specifically selected on the basis of the quality and validity of ADHD or ASD outcome definitions. From a total of 56 identified studies, commentaries, and editorials of relevance, we critically reviewed nine studies with original data that satisfied our inclusion criteria and three meta-analyses. Most studies that have reported positive findings are difficult to interpret because they have important biases, notably a high degree of selection bias, variability in selection and adjustment for various potential confounders, and unmeasured familial confounding. When unobserved familial confounding through sibling analysis was controlled for, associations weakened substantially. This suggests that residual confounding from shared genetic and environmental factors may have caused an upward bias in the original observations. According to the current scientific evidence, in utero exposure to acetaminophen is unlikely to confer a clinically important increased risk of childhood ADHD or ASD. The current level of evidence does not warrant changes to clinical guidelines on the treatment of fever or pain in pregnancy. Prospective research designed to account for familial and psychosocial environmental factors related to both maternal use of acetaminophen and children's neurodevelopment should be undertaken.
对乙酰氨基酚是一种常见的非处方药物,最近它在孕妇中的使用引起了媒体的广泛关注。在这篇临床观点文章中,我们讨论了已发表文献中关于孕期母亲使用对乙酰氨基酚对孩子患注意力缺陷多动障碍(ADHD)和自闭症谱系障碍(ASD)风险影响的优势和局限性。纳入的研究是根据ADHD或ASD结局定义的质量和有效性专门挑选的。在总共56项已确定的相关研究、评论和社论中,我们严格审查了9项有原始数据且符合我们纳入标准的研究以及3项荟萃分析。大多数报告有阳性结果的研究难以解释,因为它们存在重要偏差,尤其是高度的选择偏差、对各种潜在混杂因素的选择和调整存在差异,以及未测量的家族混杂因素。当通过兄弟姐妹分析控制未观察到的家族混杂因素时,关联度大幅减弱。这表明来自共享遗传和环境因素的残余混杂可能导致了原始观察结果的向上偏差。根据目前的科学证据,子宫内接触对乙酰氨基酚不太可能导致临床上儿童患ADHD或ASD的风险显著增加。目前的证据水平不支持改变关于孕期发热或疼痛治疗的临床指南。应该开展前瞻性研究,以考虑与母亲使用对乙酰氨基酚和儿童神经发育相关的家族和社会心理环境因素。